ArticleThe Journal of clinical investigation2000

Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction.

H N Lode et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.